Agreements reached under this partnership
Business Alliances- 1
Exclusive development and commercialization in Japan of Stempeucel®, an allogeneic mesenchymal stromal cell product for critical limb ischemia, under our development code MDNT-03
- 2
Advancement of development in Japan
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
We plan to submit the clinical trial notification by the end of September 2026 and begin dosing subjects in early 2027.
The impact on results for the fiscal year ending September 2026 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | STEMPEUTICS RESEARCH PVT LTD |
| Alliance partner's location | Bengaluru, Karnataka, India |
| Type of alliance | Business Alliances |
| Details of the alliance | Exclusive development and commercialization in Japan of Stempeucel®, an allogeneic mesenchymal stromal cell product for critical limb ischemia, under our development code MDNT-03, Advancement of development in Japan |
| Numerical targets under the alliance | We plan to submit the clinical trial notification by the end of September 2026 and begin dosing subjects in early 2027. |
| Date of board resolution | 2 July 2026 |
| Contract Date | 27 October 2025 |
| Impact on Business Performance | The impact on results for the fiscal year ending September 2026 is expected to be immaterial. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.We obtained visibility into the development strategy in Japan through discussions with the PMDA and other activities, and confirmed the feasibility of development toward conducting clinical trials and obtaining approval in Japan.